文献速递白血病

突破骨髓屏障:外周血作为急性髓系白血病可测量残留病检测的门户

Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous Leukemia.
PubMed 文献 · Am J Hematol · 2025-01-07

该综述讨论外周血检测用于急性髓系白血病可测量残留病评估的现状,重点介绍可跨亚型检测残留病的二代测序方法;指出当前残留病分析依赖有创、连续的骨髓活检,而外周血采样可提高检测频率并更好反映恶性克隆的时间动态,欧洲白血病网已针对特定遗传学异常推荐外周血检测残留病。

要点

  • 当前急性髓系白血病可测量残留病分析依赖有创、连续的骨髓活检,影响样本可及性与处理时间及患者体验。
  • 外周血采样可提高检测频率并更好反映恶性克隆的时间动态,同时避免额外有创操作。
  • 欧洲白血病网已针对特定遗传学异常推荐外周血用于急性髓系白血病可测量残留病检测。

核心结论

  • 外周血检测用于急性髓系白血病可测量残留病评估已显示前景,欧洲白血病网针对特定遗传学异常推荐外周血检测。

研究设计与样本

  • 综述,讨论外周血检测用于急性髓系白血病可测量残留病评估的现状,重点为可跨急性髓系白血病亚型检测残留病的二代测序方法。

主要发现

  • 当前可测量残留病分析依赖有创、连续的骨髓活检,使样本可及性与处理时间复杂化并对患者体验产生负面影响。
  • 外周血采样允许更频繁的检测间隔并更好反映恶性克隆的时间动态,同时避免患者接受额外有创操作。

关键数值与推荐

  • 欧洲白血病网针对特定遗传学异常推荐外周血用于急性髓系白血病可测量残留病检测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is a genetically heterogeneous disease with high rates of relapse after initial treatment. Identifying measurable residual disease (MRD) following initial therapy is essential to assess response, predict patient outcomes, and identify those in need of additional intervention. Currently, MRD analysis relies on invasive, serial bone marrow (BM) biopsies, which complicate sample availability and processing time and negatively impact patient experience. Additionally, finding a positive result can generate more questions than answers, causing anxiety for both the patient and the provider. Peripheral blood (PB) evaluation has shown promise in detecting MRD and is now recommended by the European Leukemia Net for AML for certain genetic abnormalities. PB-based sampling allows for more frequent testing intervals and better temporal resolution of malignant expansion while sparing patients additional invasive procedures. In this review, we will discuss the current state of PB testing for MRD evaluation with a focus on next-generation sequencing methodologies that are capable of MRD detection across AML subtypes.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Butler JT, Yashar WM, Swords R, et al. Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous Leukemia. Am J Hematol. 2025. PMID: 39777414. doi:10.1002/ajh.27586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。